Coldstream Capital Management Inc. Has $4.92 Million Holdings in Amgen Inc. $AMGN

Coldstream Capital Management Inc. decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 17,432 shares of the medical research company’s stock after selling 2,441 shares during the period. Coldstream Capital Management Inc.’s holdings in Amgen were worth $4,919,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in AMGN. Laurel Wealth Advisors LLC lifted its holdings in Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after purchasing an additional 6,676,575 shares during the last quarter. Norges Bank acquired a new position in Amgen during the second quarter valued at approximately $1,663,726,000. Capital World Investors raised its position in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. National Bank of Canada FI raised its position in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after buying an additional 687,735 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 2.7%

Shares of Amgen stock opened at $351.48 on Thursday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company’s fifty day simple moving average is $359.46 and its 200-day simple moving average is $326.94. The company has a market cap of $189.47 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 3.58 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the prior year, the company earned $5.31 EPS. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s dividend payout ratio is currently 70.84%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. BMO Capital Markets upped their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. UBS Group lifted their target price on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Rothschild & Co Redburn boosted their target price on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Barclays initiated coverage on Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target on the stock. Finally, Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $354.00.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.